Ginkgo Bioworks (DNA) to Release Earnings on Thursday

Ginkgo Bioworks (NYSE:DNA) will likely be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Ginkgo Bioworks to announce earnings of ($0.8950) per share and revenue of $24.05 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Ginkgo Bioworks (NYSE:DNA) last announced its earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.21) by ($0.18). Ginkgo Bioworks had a negative return on equity of 56.08% and a negative net margin of 215.41%.The firm had revenue of $19.00 million during the quarter, compared to the consensus estimate of $42.93 million.

Ginkgo Bioworks Stock Up 4.9%

NYSE DNA opened at $9.38 on Wednesday. Ginkgo Bioworks has a twelve month low of $5.37 and a twelve month high of $17.58. The firm has a market capitalization of $612.44 million, a PE ratio of -1.75 and a beta of 1.78. The stock’s 50 day moving average is $8.81 and its 200 day moving average is $8.34.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quarry LP bought a new stake in shares of Ginkgo Bioworks during the third quarter valued at approximately $29,000. Raymond James Financial Inc. bought a new position in Ginkgo Bioworks in the 2nd quarter valued at approximately $29,000. Daiwa Securities Group Inc. bought a new position in Ginkgo Bioworks in the 2nd quarter valued at approximately $71,000. New York State Common Retirement Fund purchased a new stake in Ginkgo Bioworks during the 2nd quarter valued at $138,000. Finally, Atom Investors LP purchased a new stake in Ginkgo Bioworks during the 4th quarter valued at $105,000. Institutional investors own 78.63% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Wall Street Zen lowered Ginkgo Bioworks from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ginkgo Bioworks in a research report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, Ginkgo Bioworks has a consensus rating of “Reduce” and a consensus target price of $8.50.

About Ginkgo Bioworks

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.